2区 · 医学
Article
作者: Hurd, Alexander R. ; Ford, Charles W. ; Sweeney, Michael T. ; Harris, Douglas W. ; Munzner, Jennifer B. ; Zurenko, Gary E. ; Marotti, Keith R. ; Dolak, Lester A. ; Skepner, Jill E. ; Bammert, Gary F. ; Graber, David R. ; Hromockyj, Alexander E. ; Mott, John E. ; Boyle, Timothy P. ; Bundy, Gordon L. ; Seest, Eric P. ; Han, Fusen ; Kamilar, Gregg M. ; Zhong, Wei-Zhu ; Palmer, John R. ; Ruble, J. Craig ; Martin, Gary E. ; Miller, Alita A. ; Hamel, Judith C. ; Banitt, Lee S. ; Barbachyn, Michael R.
ABSTRACT:QPT-1 was discovered in a compound library by high-throughput screening and triage for substances with whole-cell antibacterial activity. This totally synthetic compound is an unusual barbituric acid derivative whose activity resides in the (−)-enantiomer. QPT-1 had activity against a broad spectrum of pathogenic, antibiotic-resistant bacteria, was nontoxic to eukaryotic cells, and showed oral efficacy in a murine infection model, all before any medicinal chemistry optimization. Biochemical and genetic characterization showed that the QPT-1 targets the β subunit of bacterial type II topoisomerases via a mechanism of inhibition distinct from the mechanisms of fluoroquinolones and novobiocin. Given these attributes, this compound represents a promising new class of antibacterial agents. The success of this reverse genomics effort demonstrates the utility of exploring strategies that are alternatives to target-based screens in antibacterial drug discovery.